RecruitingAnaplastic Large Cell Lymphoma, ALK-NegativeFollicular Helper T-Cell LymphomaFollicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

Eligible age

18–75 yrs

Accepts

All genders

Locations

32 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This phase III trial compares the effect of high dose chemotherapy and the patients' own (autologous) stem cells to observation only in patients with peripheral T-cell lymphoma who achieved a complete response after initial chemotherapy. Usual treatment after a complete response may include observation or high dose chemotherapy followed by an autologous stem cell transplant, however, it is not known if a transplant if beneficial. Giving chemotherapy before a stem cell transplant helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. Stem cells removed prior to treatment are then returned to the patient to replace the blood forming cells that were destroyed by the chemotherapy. Giving high dose chemotherapy followed by an autologous stem cell transplant may be more effective compared to observation only in treating patients with peripheral T-cell lymphoma who have achieved a complete response after initial chemotherapy.

Sponsor: Eastern Cooperative Oncology Group

You may qualify if…

✓ Patient must be 18 to 75 years of age
✓ Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-2
✓ Patient must have histologically proven peripheral T-cell lymphoma (PTCL) in one of the following categories:
✓ Anaplastic large cell lymphoma (ALCL) ALK-negative
✓ Angioimmunoblastic T-cell lymphoma (AITL)
✓ Nodal PTCL with follicular helper T cell (TFH) phenotype
✓ Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS)
✓ Patient must have undergone induction treatment with an anthracycline based chemotherapy.